CME for Physicians
CNE for Nurses
CPE for Pharmacists
CANCER EDUCATION FOR PHYSICIANS, NURSES, AND PHARMACISTS - Taught by the Experts

Co-Chairs

Edward B. Garon MD
Edward B. Garon , MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
 
Paul A. Bunn MD
Paul A. Bunn , Jr. , MD
Distinguished Professor
James Dudley Chair in Lung Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Denver, CO
 
H Jack West MD
H Jack West , MD
Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
President and CEO
Global Resource for Advancing Cancer Education (GRACE)
Seattle, WA
 
Roy S. Herbst MD, PhD
Roy S. Herbst , MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
 

Faculty

Edward B. Garon MD
Edward B. Garon , MD
Associate Clinical Professor
Department of Medicine
Director, Thoracic Oncology Program
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
 
Ronald B. Natale MD
Ronald B. Natale , MD
Director of the Lung Cancer Clinical Research Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
 
Greg  Riely MD
Greg Riely , MD
Medical Oncologist
Thoracic Oncology Service
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
 
Marianne  Davies DNP, ACNP, AOCNP
Marianne Davies , DNP, ACNP, AOCNP
Clinical Instructor in Nursing
Thoracic Oncology Program
Yale Comprehensive Cancer Center
Yale Schools of Nursing and Medicine
New Haven, CT
Oncology Pharmacist Faculty
 
Richard  Gralla MD, FACP
Richard Gralla , MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
 
Jim  Koeller MS
Jim Koeller , MS
Professor,
University of Texas at Austin
College of Pharmacy,
Pharmacotherapy Division
Adjoint Professor
University of Texas Health Science Center at San Antonio
School of Medicine, Pharmacotherapy Education & Research
University of Texas Health Science Center at San Antonio
San Antonio, TX
 
Walter  Curran MD
Walter Curran , Jr. , MD
Executive Director, Winship Cancer Institute
Associate Vice President, Cancer,
Woodruff Health Sciences Center
Lawrence W. Davis Professor and Chairman of Radiation Oncology
Group Chairman and Principal Investigator, NRG
Atlanta, GA
 
Joel  Neal MD, PhD
Joel Neal , MD, PhD
Assistant Professor
Department of Medicine
Division of Oncology
Member, Stanford Cancer Institute
Stanford Clinical Cancer Center
Stanford, CA
 
Deborah  Wong MD, PhD
Deborah Wong , MD, PhD
Professor, Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Oncology Nursing Faculty
 
12th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head & Neck Cancer

Agenda

7:00AM Registration and Full Buffet Breakfast
8:00AM Welcome, Introductions and CME/CE Pre Test
Dr. Paul Bunn
SESSION #1: SMALL CELL LUNG CANCER (SCLC): New & Emerging Strategies Replacing the 30-Year-Old Standard of Care
8:10AM Therapeutic Strategies for Small Cell Lung Cancer (SCLC): Systemic & Maintenance Therapy for Treatment-Naïve SCLC Patients, and CNS Therapy (local/systemic)
  • Mono-versus Dual Checkpoint Inhibition?
  • Checkpoint Inhibition Plus Chemotherapy/Targeted Therapy?
  • Prophylactic Cranial Radiation, and, Concomitant Radiation Therapy with Immune Therapy?
Dr. Paul Bunn
8:25AM Molecular Biomarkers: Developing Precision Medicine Strategies for SCLC
  • Is Tumor Mutational Burden (TMB) Ready for Prime Time as a Predictive Marker for SCLC?
  • Pros and Cons of Blood-Based TMB Versus Tissue-Based TMB?
  • Is There a Role for PD-L1 Expression as a Biomarker in SCLC?
  • Are There Other Biomarkers for SCLC Potentially Ready for Prime Time?
Dr. H. Jack West
8:40AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

Dr. Paul Bunn (Moderator)
8:50AM Salvage Therapy for Small Cell Lung Cancer: Antibody Drug Conjugates (ADCs), Other Novel Targeted Therapy Strategies, Checkpoint Inhibition and Chemotherapy
  • Inhibiting Delta-Like Ligand 3 (DLL3) and the Roles of SN-38 ADCs
  • Inhibiting Trophoblast Cell Surface Antigen 2 (TROP-2)
  • PARP Inhibition in Combination Strategies
  • RNA-Polymerase II Inhibition?
  • Checkpoint Inhibition
  • Chemotherapy
 
9:05AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
SESSION #2: Strategies for EARLY-STAGE NSCLC and OLIGOMETASTATIC NSCLC
9:20AM Early-Stage NSCLC:
  • Checkpoint Inhibition for Unresectable Stage III NSCLC
  • Are there potentially curable Stage III NSCLC patients treated with systemic therapy?
  • Neo-adjuvant and Adjuvant Trials
 
9:35AM Oligometastatic NSCLC:
  • Current data on therapeutic strategies for oligometastatic NSCLC
  • Local therapy with or without systemic therapy
  • Is there a standard of care?
 
9:50AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
10:00AM BREAK
SESSION #3: Strategies for NON-SQUAMOUS NSCLC and SQUAMOUS NSCLC
10:15AM DEBATE #1: Should a medical oncologist delay therapy for a treatment-naïve NSCLC patient while waiting for molecular testing results to determine if a driver mutation exists?
  • YES (wait for driver mutation test results before initiating therapy) (Dr. Paul Bunn)
  • NO (start treatment without waiting for mutation testing results) ( )
10:30AM DEBATE #2: Total Mutation Burden is a necessary clinical tool for managing NSCLC patients today.
  • YES(Dr. H. Jack West)
  • NO( )
10:45AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

Dr. Paul Bunn (Moderator)
11:00AM What are the therapeutic options for initial therapy of NON-SQUAMOUS NSCLC?
  • Current algorithms; new and emerging therapies
  • Targeting PD-1, PD-L1, (Stratifying by PD-L1 Expression and TMB)
  • Targeting CTLA-4
  • Targeting EGFR, ALK, ROS1, and New and Emerging Driver Mutations
  • Current and emerging various combinations of Immune & targeted therapies & chemotherapy
  • Chemotherapy monotherapy and in various combinations with Immune & targeted therapies
 
11:15AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
11:30AM What are the therapeutic options for initial therapy of SQUAMOUS NSCLC?
  • Current algorithms and new and emerging therapies
  • Targeting VEGFR2
  • Targeting PD-1, PD-L1, CTLA-4
  • Targeting EGFR, ALK, ROS1, BRAF
  • Current and emerging various combinations of Immune & targeted therapies & chemotherapy
  • Chemotherapy monotherapy and in various combinations with Immune & targeted therapies
 
11:45AM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
SESSION #4: LUNCH "With the Professors" 3 Options (each option provides 0.75 hours of CME/CE credit)
12:00PM Integrating QI into Community Oncology Practices for Lung Cancer  
12:00PM Physician Reimbursement Update  
12:00PM Managing Immune Therapy irAEs  
SESSION #5: The New Therapeutic Landscapes for ALK & ROS-1 REARRANGEMENT & EGFR-POSITIVE NSCLC
1:00PM DEBATE #3: Should we use the most effective anti-EGFR or anti-ALK/ROS1-directed therapy "up- front"? Or should we save it for relapse after Acquired Resistance (AR)?
  • Use most effective agent "up front" ( )
  • Save it for relapse after AR (Dr. Paul Bunn)
1:15PM ALK-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents) initial therapy of SQUAMOUS NSCLC?
  • Should any of the FDA-approved anti-ALK targeted therapies be considered as the standard of care for treatment-naïve ALK-positive NSCLC patients?
  • What are the current expert academic strategies for optimal sequencing of anti-ALK TKIs?
  • What are the strategies for intra-cranial disease control in ALK-positive NSCLC?
Dr. Paul Bunn
1:30PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

Dr. Paul Bunn (Moderator)
1:45PM EGFR-Positive-NSCLC: 1st-Line Therapies and Sequencing Options: (1st, 2nd & 3rd-generation agents) initial therapy of SQUAMOUS NSCLC?
  • Should any of the EGFR-directed therapies be considered as the 1st-line standard of care?
  • What is the role for AR-mutation testing after patients relapse on up-front ant-EGFR therapy? And what is the test? and what is it looking for?
  • Should any patients with EGFR mutations receive immunotherapy? If Yes? Who? When?
  • What is the role for immune therapy in patients with EGFR mutations?
 
2:00PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
2:15PM What are the "SALVAGE" NSCLC Therapy Standards of Care? How can they be optimally sequenced?
  • Chemotherapy
  • Targeted Therapy
  • Checkpoint Inhibition Targeting PD-1, PD-L1, CTLA-4
 
2:30PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
2:45PM BREAK
SESSION #6: New & Emerging NSCLC Driver Mutations "BEYOND" EGFR & ALK/ROS1: Optimal Therapies & Testing
3:05PM Treatment Options for New & Emerging NSCLC Mutations: Maximizing Targeted Therapy Outcomes
  • How does Broader FDA-approved NGS testing change what medical oncologists are using as standards of care who are treating NSCLC?
  • What NSCLC molecular targets and corresponding targeted therapies are relevant beyond EGFR and ALK/ROS1? MET, MET exon 14, RET, NTRK1/2/3,? and others?
 
3:25PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
3:40PM DEBATE #4: Plasma-based NGS testing versus Tissue-based NGS testing: Are these interchangeable?
  • Plasma-based NGS testing (Dr. Edward Garon)
  • Tissue-based NGS testing ( )
4:00PM Molecular Testing for NSCLC Patients: Where are we today? What's coming?
  • Testing for PD-L1 expression and TMB
  • Predictive biomarkers and optimal testing for mutation-positive NSCLC
  • Plasma-based versus tissue-based biopsy testing (NGS and TMB)
Dr. Edward Garon
4:15PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

Dr. Edward Garon (Moderator)
SESSION #7: Head & Neck Cancer: Systemic Therapies
4:30PM Squamous Cell Cancer of the Head & Neck (SCCHN): New Advances with Checkpoint Inhibition-Based Strategies
  • For patients with progression on platinum-based therapy only?
  • Is there a role in up front therapy for Checkpoint Inhibition?
 
4:45PM Expert Panel Discussion and Audience Q & A

The expert panel answers the queued-up audience questions submitted via their iPads or their other "smart devices" & from floor microphones, and also engages in a lively exchange of opinions.

  (Moderator)
4:55PM CME/CE Post Test
5:00PM Adjourn

Overview

This symposium addresses the learning objectives resulting from our comprehensive Needs Assessment and professional Quality Performance Practice Gaps identified. The review of the relatively existing, new and emerging novel and established immune therapies and targeted therapies and many expanded label claims, plus key chemotherapy applications including those used in combinations with immune and targeted therapies that are included in our Practice Gap identification and analyses of the Needs Assessment, have necessitated a focus on those therapies that have either recently become components of new and standards of care or are expected to become integrated into the current standards of care, e.g., the NCCN, ASCO, or ASCO/CAP guidelines, etc., either as combination therapy regimens that involve immune or targeted therapies, or immune or targeted therapies used in sequence with immune, targeted and chemotherapy for lung cancer and Head Neck cancer. In other words, despite the well-deserved high-level of interest that immune therapies are providing the cancer community and cancer patients today, both immune therapy and targeted therapy, as well as essential key chemotherapy, all three modalities will remain essential components of the mainstay of systemic therapy for treating thoracic malignancies for the foreseeable future.

The combination and sequential use of immune therapies (especially with the many new drugs and newly approved and expected new indications for various monotherapy and combinations of immune therapy plus other agents) and targeted therapies (and also, especially with the new anti-EGFR, anti-ALK, anti-ROS1, and MET, MET-exon 14, RET and NTRK1/2/3 agents) plus chemotherapy, continues to evolve in many significant ways from the traditional, systemic anti-cancer regimens used to date. And because immune therapies, novel targeted and chemotherapies may either replace, be options for and/or be used in combination with existing systemic therapy standards of care, it is vital that the current, new and emerging investigational regimens are well understood by oncologists, pathologists, radiologist oncologists, surgical oncologists, nurses, nurse practitioners, pharmacists and other HCPs, especially in the community and private practice and non-academic hospital settings. During the past few years, and especially the past 12 months the FDA has approved several new immune therapies and targeted therapies and expanded label claims of several FDA-approved immune and targeted therapies for thoracic malignancies, and especially SCLC. Many others are under active clinical investigation. These therapies are either replacing or adding to existing components of established systemic therapy regimens. This is the “real world” that is addressed in the July 20, 2019 symposium in San Francisco and corresponding Internet webinar enduring materials. Thus, the inevitable emergence of new and investigational combinations of immune plus targeted therapies and chemotherapies is the fundamental reason for the generation of the Quality Performance Practice Gaps that lead to the need for this symposium. In addition, clinicians today are also faced with so many investigational experimental clinical trials options. This highly practical, case-based symposium addresses their educational needs to adequately close their Quality Performance Practice Gaps and thus, improve patient outcomes.


Educational Need

In 2018, an estimated 234,030 adults (121,680 men and 112,350 women) in the United States will be diagnosed with lung cancer—a total of both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). And in 2018, an estimated 150,040 people will die from all lung cancers. SCLC: Approximately 30,000 people will be diagnosed with SCLC in 2018. Approximately 70% of the SCLC patients present with stage IV disease, where the treatment approach is only palliative. The SCLC prognosis is the poorest among all types of lung cancer, with an overall and dismal survival rate at 5 years of between 2 and 5%.

NSCLC represents about approximately 85 to 90% of all lung cancers. Survival rates for NSCLC patients vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancers are diagnosed at late stages of disease, especially Stages 2 and mostly 3, the five-year survival rate for Stage 4 NSCLC is approximately two percent.

Head & Neck Cancer accounts for about 4% of all cancers in the United States. This year, an estimated 64,690 people (47,650 men and 17,040 women) will develop head and neck cancer. While younger people can develop the disease, most people are older than 50 when they are diagnosed.

QUALITY PERFORMANCE PRACTICE GAPS

There are many major Quality Performance Practice Gaps that were identified in our Needs Assessment that were identified and prepared for July 20, 2019 symposium in San Francisco that need to be overcome in order to help improve outcomes in NSCLC, SCLC and Head & Neck Cancer patients as they relate to the topics of this proposed symposium. These “Gaps” were identified and developed by comparing the “ideal or best” practices as we determined from our interviews with the academic SCLC medical oncologist experts that we interviewed in October 2018 with the general practices of medical oncologists, Advanced Nurse Practitioners, Physician Assistants, pharmacists and nurses, and other allied healthcare professionals treating Small Cell Lung Cancer from focus our groups in October 2018. The PRACTICE GAPS Practice Gaps were used to develop the learning objectives. Here are a few examples of PRACTICE GAPS.

  1. The lack of widespread awareness of the ability to enroll eligible Stage 3 NSCLC patients in an ongoing trial to receive atezolizumab or pembrolizumab investigational therapy as options among others to potentially improve outcome in early-stage NSCLC is a Quality Performance Practice Gap.
  2. A Practice Gap regarding treating nonsquamous NSCLC is which patients are candidates for which therapies: Immune Checkpoint Inhibition (monotherapy)? Immune Checkpoint Inhibition (in combination therapy with other Checkpoint Inhibitors or other immune therapies (such as is discussed a few pages from now regarding the combination of durvalumab or pembrolizumab with the immune therapy, IDO1 (Indoleamine 2,3-dioxygenase 1) to improve NSCLC outcomes, or even with chemotherapy.
  3. The lack of widespread awareness of the opportunity to enroll eligible NSCLC patients in the various ongoing pembrolizumab trials to receive this investigational agent as one option to possibly improve outcome is a Practice Gap.
  4. The lack of widespread awareness of the recent FDA 1st-line approval of pembrolizumab in combination with chemotherapy in squamous NSCLC in late 2018, and how this new option for treatment-naïve squamous NSCLC fits in with other 1st-line checkpoint inhibition regimens is a Quality Performance Practice Gap.
  5. The lack of widespread awareness of the August 2018 FDA approval of nivolumab for 3rd-line SCLC to help improve patient outcome is a major Quality Performance Practice Gap.
  6. The lack of widespread awareness of the options within the SCLC NCCN Guidelines to use nivolumab, nivolumab plus ipilimumab, or pembrolizumab in the second-line SCLC setting is a major Quality Performance Practice Gap.
  7. The lack of widespread awareness of the opportunity to enroll eligible NSCLC patients in the various ongoing nivolumab trials to receive this investigational agent as one option to possibly improve outcome is a Practice Gap.
  8. The lack of widespread awareness of the ability to enroll eligible Stage 3 NSCLC patients in trials to receive nivolumab or pembrolizumab as investigational consolidation immunotherapy as options among others to potentially improve outcome in Stage 3 NSCLC is a Quality Performance Practice Gap.

Target Audience

The target audience includes both academic/hospital-based, and, also community-based/private practice oncologists, pathologists, immunologists, diagnostic radiation clinicians, radiation oncologists, surgical oncologists, fellows, cancer pharmacists, cancer nurses, Advanced Nurse Practitioners, Oncology Physician Assistants and other allied healthcare professionals (HCPs) who treat and care for all NSCLC, SCLC, and Head & Neck Cancer patients. Although some of the focus is on community-based practices, because of the pace at which all data is changing, all clinicians in all practice settings, including academia, are targeted, including research-based oncologists and allied HCPs.


Learning Objectives

Physician
  1. Understand how to select from among all options to provide the optimal therapy for patients with Small Cell Lung Cancer in the treatment-naïve and salvage settings.
  2. Understand how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Compare and Contrast Molecular Testing Methodologies for Small Cell Lung Cancer.
  4. Evaluate when to order NGS testing for treatment-naïve patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Compare and contrast the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Compare and contrast the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Evaluate the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Evaluate the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. Compare and contrast the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Compare and contrast the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy
  11. Understand how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Compare and contrast the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Evaluate the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Nurse
  1. Understand how to select from among all options to provide the optimal therapy for patients with Small Cell Lung Cancer in the treatment-naïve and salvage settings.
  2. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
  4. Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Review the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  11. Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.
Pharmacist
  1. Understand how to select from among all options to provide the optimal therapy for patients with Small Cell Lung Cancer in the treatment-naïve and salvage settings.
  2. Recall how to select from among all options to provide the optimal therapy for treatment-naïve patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  3. Describe Molecular Testing Methodologies for Small Cell Lung Cancer.
  4. Review the NGS testing methodologies for patients with nonsquamous or squamous NSCLC, including for those patients with EGFR mutations, ALK, ROS1 rearrangements and the newer driver mutations.
  5. Define the immune and targeted therapy options for treating patients with nonsquamous or squamous Non-Small Cell Lung Cancer in both the treatment naïve and salvage settings.
  6. Identify the various immune therapy and chemotherapy options in treatment-naïve NSCLC without driver mutations in patients with high, low or no expression of PD-L1.
  7. Recall the scenarios for when, if ever, to temporarily discontinue, and when to resume immune therapy in a NSCLC patient that is responding to therapy.
  8. Review the large number of open clinical trials offering various combinations of immune and targeted therapies for Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Head & Neck Cancer as possible options for enrolling eligible patients to possibly improve outcome.
  9. List the increasing number of options for treating NSCLC patients with an EGFR-directed therapy across all lines of therapy.
  10. Review the increasing number of options for treating NSCLC patients with an ALK-directed therapy across all lines of therapy.
  11. Describe how to apply the various sequencing strategies for managing acquired resistance to anti-EGFR and anti-ALK therapy, including when to use the most effective of the three generations of EGFR-directed and ALK-directed TKI therapies “up front” versus saving them for salvage therapy.
  12. Analyze the various predictive and prognostic markers including PD-L1, Tumor Mutation Burden (TMB) and smoking history for patients with nonsquamous or squamous Non-Small Cell Lung Cancer.
  13. Evaluate the various systemic and local therapies for Early-Stage NSCLC patients, including oligometastatic disease.
  14. Understand the pros and cons of prophylactic cranial irradiation in NSCLC considering the advances with TKIs and other systemic therapy.
  15. Review the new FDA-approved and emerging immune therapies, targeted therapies and combinations with and without chemotherapy for squamous cell Head & Neck cancer.
  16. Describe the opportunities to address and improve priorities for the National Quality Strategy and Quality Improvement.

CME/CE Accreditation and Credit Designation

Physicians

The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The BioMedical Learning Institute designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 8.25 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Pharmacists

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN:
Credits: 8.25 hours (0.825 ceu)
Type of Activity:

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.


Activity Location

San Francisco Airport Marriott Waterfront
1800 Old Bayshore Highway
Burlingame, CA 94010
(650) 692-9100

Exhibit Information

There is an opportunity to exhibit at this symposium. Please send an email to exhibits@bmli.com for more information or call 214-269-2014

EXHIBIT FEES:

  • The fee for a 6-foot tabletop display and 2 discounted registrations for symposium and all meals is $3,999.
  • The fee for a 6-foot tabletop display and 3 discounted registrations for symposium and all meals is $4,999.
  • The fee for 2 6-foot tabletop displays and 2 discounted registrations for symposium and all meals is $5,999.
  • The fee for 2 6-foot tabletop displays and 3 discounted registrations for symposium and all meals is $6,999.
 

Educational Support

Sincere appreciation is extended to companies providing support for this independent educational activity.

Takeda Oncology
Bristol-Myers Squibb
Celgene
Loxo Oncology
Additional commercial support pending

Cancer Grace

NCCN